Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.53T
24h Vol:
$5.13B
Dominance:
MSFT:5.13%
Stocklytics Platform
BETA
Instrument logo  EYPT

EyePoint Pharmaceuticals Inc

EYPT
69 / 100
High Growth
$26.67arrow_drop_up0.45%$0.12

Performance History

Stocklytics logo
Key Stats
Open$26.06
Prev. Close$26.10
EPS-2.66
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.29B
PE Ratio-
LOWHIGH
Day Range25.63
27.88
52 Week Range2.21
30.99
Ratios
P/B Ratio22.12
Revenue$42.52M
Operating M. %-94.71%
Earnings$0.00
Earnings Growth %2.06%
EBITDA Margin %-190.63%
ROE %-102.73%
EPS-2.66

Score Breakdown

69vs 53. Market Avg.

All Score 69 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

EYPTMARKET
Value3439
Quality5140
Ownership319
Growth9046
Dividends-37
check_circle

EyePoint Pharmaceuticals Inc's Price growth average in the last 3 years of 200.78% is great compared to market average of 6.04%. This indicates EYPT could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$768.36
24H (%)arrow_drop_down-0.46%
24H ($)-$3.55
MARKET CAP$730.10B
PRICE$522.66
24H (%)arrow_drop_down-0.50%
24H ($)-$2.66
MARKET CAP$483.43B
PRICE$160.74
24H (%)arrow_drop_down-0.03%
24H ($)-$0.04
MARKET CAP$387.25B
PRICE$128.90
24H (%)arrow_drop_up0.04%
24H ($)$0.06
MARKET CAP$326.66B

About EyePoint Pharmaceuticals Inc (EYPT)

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, engages in developing and commercializing therapeutics to enhance the lives of patients with serious eye disorders in the United States, China, and the United Kingdom. Its commercial products include YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU for the treatment of postoperative inflammation. The company's pipeline leverages its Durasert technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal treatment that is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jay S. Duker M.D.
Headquarters
Watertown
Employees
144
Exchange
NASDAQ
add EyePoint Pharmaceuticals Inc to watchlist

Keep an eye on EyePoint Pharmaceuticals Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is EyePoint Pharmaceuticals Inc's (EYPT) price per share?

The current price per share for EyePoint Pharmaceuticals Inc (EYPT) is $28.17. The stock has seen a price change of $1.94 recently, indicating a 7.31% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for EyePoint Pharmaceuticals Inc (EYPT)?

For EyePoint Pharmaceuticals Inc (EYPT), the 52-week high is $30.99, which is 8.78% from the current price. The 52-week low is $2.21, the current price is 1.19K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is EyePoint Pharmaceuticals Inc (EYPT) a growth stock?

EyePoint Pharmaceuticals Inc (EYPT) has shown an average price growth of 200.78% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying EyePoint Pharmaceuticals Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is EyePoint Pharmaceuticals Inc (EYPT) stock price performance year to date (YTD)?

As of the latest data, EyePoint Pharmaceuticals Inc (EYPT) has a year-to-date price change of 26.51%. Over the past month, the stock has experienced a price change of 6.9%. Over the last three months, the change has been 363.25%. Over the past six months, the figure is 144.34%. Looking at a longer horizon, the five-year price change stands at 9.16%.

question_mark
Is EyePoint Pharmaceuticals Inc (EYPT) a profitable company?

EyePoint Pharmaceuticals Inc (EYPT) has a net income of -$100.15M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 83.43% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -94.71% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $42.52M, with a revenue growth rate of 2.7%, providing insight into the company's sales performance and growth. The gross profit is $35.48M. Operating income is noted at -$81.75M. Furthermore, the EBITDA is -$81.06M.

question_mark
What is the market capitalization of EyePoint Pharmaceuticals Inc (EYPT)?

EyePoint Pharmaceuticals Inc (EYPT) has a market capitalization of $1.39B. The average daily trading volume is 893.93K, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.